Home > Research Projects > COVID-19 registry for patients with inflammatory rheumatic disease

COVID-19 registry for patients with inflammatory rheumatic disease

In light of the COVID-19 pandemic, the group has been actively involved in setting up the German and European COVID-19 register. Prof Anja Strangfeld and PD. Anne Regierer are members of the steering group of the German registry and Prof. Dr Anja Strangfeld is a member of the steering committee of the European registry. Through international cooperation, important insights into the special situation of patients with autoimmune diseases under immunosuppression could be gained very quickly.

Head of project

Responsible persons at the DRFZ

Prof. Dr. med. Anja Strangfeld
Head of Programme Area 2,  Epidemiology and Health Services Research
Group leader: Pharmacoepidemiology

PD Dr. med. Anne Regierer
Programme Area 2,  Epidemiology and Health Services Research
Group leader: Register Research in Rheumatology

www.covid19-rheuma.de

Prof. Dr. med. Anja Strangfeld
Head of Programme Area 2,  Epidemiology and Health Services Research
Group leader: Pharmacoepidemiology

https://rheum-covid.org/

Selected publications

Gehe zum Ende des Sliders
Strangfeld A, Schäfer M, Gianfrancesco MA, Lawson-Tovey S, Liew JW, Ljung L, Mateus EF, Richez C, Santos MJ, Schmajuk G, Scirè CA, Sirotich E, Sparks JA, Sufka P, Thomas T, Trupin L, Wallace ZS, Al-Adely S, Bachiller-Corral J, Bhana S, Cacoub P, Carmona L, Costello R, Costello W, Gossec L, Grainger R, Hachulla E, Hasseli R, Hausmann JS, Hyrich KL, Izadi Z, Jacobsohn L, Katz P, Kearsley-Fleet L, Robinson PC, Yazdany J, Machado PM.

Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Ann Rheum Dis. 2021 Jan 27 Open Access
Regierer AC, Hasseli R, Schäfer M, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter JG, Schmeiser T, Schulze-Koops H, Strangfeld , Voll RE, Specker C, Mueller-Ladner U.

TNFi is associated with positive outcome, but JAKi and rituximab are associated with negative outcome of SARS-CoV-2 infection in patients with RMD.

RMD Open. 2021 Oct 22:7(3). Open Access
Ugarte-Gil MF, Alarcón GS, Izadi Z, Duarte-García A, Reátegui-Sokolova C, Clarke AE, Wise L, Pons-Estel GJ, Santos MJ, Bernatsky S, Ribeiro SLE, Emadi SA, Sparks JA, Hsu TY, Patel NJ, Gilbert EL, Valenzuela-Almada MO, Jönsen A, Landolfi G, Fredi M, Goulenok T, Devaux M, Mariette X, Queyrel V, Romão VC, Sequeira G, Hasseli R, Hoyer BF, Voll RE, Specker C, Baez R, Castro-Coello V, Maldonado FH, Reis NE, Ferreira GAA, Monticielo OAA, Sirotich E, Liew JW, Hausmann JS, Sufka P, Grainger R, Bhana S, Costello W, Wallace ZS, Jacobsohn L, Taylor T, Ja C, Strangfeld , Mateus EF, Hyrich KL, Carmona L, Lawson-Tovey S, Kearsley-Fleet L, Schäfer M, Machado PM, Robinson PC, Gianfrancesco M, Yazdany J.

Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance.

Ann Rheum Dis. 2022 Feb 16 Open Access
Hasseli R, Mueller-Ladner U, Hoyer BF, Krause A, Lorenz HM, Pfeil A, Richter JG, Schäfer M, Schmeiser T, Strangfeld (Ersthelfer) , Schulze-Koops H, Voll RE, Specker C, Regierer .

Older age, comorbidity, glucocorticoid use and disease activity are risk factors for COVID-19 hospitalisation in patients with inflammatory rheumatic and musculoskeletal diseases.

RMD Open. 2021 Jan 23:7(1). Open Access

AG Strangfeld

Pharmacoepidemiology

AG Regierer

Register Research in Rheumatology